Resat Cinar, Grzegorz Godlewski, Jie Liu, Joseph Tam, Tony Jourdan, Bani Mukhopadhyay, Judith Harvey‐White, George Kunos – 6 July 2013 – Obesity is associated with increased activity of two lipid signaling systems (endocannabinoids [ECs] and ceramides), with both being implicated in insulin resistance. Cannabinoid‐1 receptor (CB1R) antagonists reverse obesity and insulin resistance, but have psychiatric side effects.

Kengo Tomita, Toshiaki Teratani, Takahiro Suzuki, Motonori Shimizu, Hirokazu Sato, Kazuyuki Narimatsu, Yoshikiyo Okada, Chie Kurihara, Rie Irie, Hirokazu Yokoyama, Katsuyoshi Shimamura, Shingo Usui, Hirotoshi Ebinuma, Hidetsugu Saito, Chikako Watanabe, Shunsuke Komoto, Atsushi Kawaguchi, Shigeaki Nagao, Kazuo Sugiyama, Ryota Hokari, Takanori Kanai, Soichiro Miura, Toshifumi Hibi – 6 July 2013 – Although nonalcoholic steatohepatitis (NASH) is associated with hypercholesterolemia, the underlying mechanisms of this association have not been clarified.

Jinghong Wan, Merieme Benkdane, Fatima Teixeira‐Clerc, Stéphanie Bonnafous, Alexandre Louvet, Fouad Lafdil, Françoise Pecker, Albert Tran, Philippe Gual, Ariane Mallat, Sophie Lotersztajn, Catherine Pavoine – 6 July 2013 – Alcoholic and nonalcoholic fatty liver disease (ALD and NAFLD) are the predominant causes of liver‐related mortality in Western countries. We have shown that limiting classical (M1) Kupffer cell (KC) polarization reduces alcohol‐induced liver injury. Herein, we investigated whether favoring alternatively activated M2 KCs may protect against ALD and NAFLD.

Mohamed Rela – 3 July 2013

C. Kristian Enestvedt, Saloni Malik, Peter P. Reese, Alexander Maskin, Peter S. Yoo, Sameh A. Fayek, Peter Abt, Kim M. Olthoff, Abraham Shaked – 2 July 2013 – Inferior outcomes are consistently observed for recipients of liver retransplantation (re‐LT) versus recipients of primary transplants. Few studies have examined the incidence and impact of biliary complications (BCs) on outcomes after re‐LT. The aim of this study was to compare patient and graft survival for re‐LT recipients with BCs (BC+) and re‐LT recipients without BCs (BC−).

Stefan Mauss, Dietrich Hueppe, Ulrich Alshuth – 28 June 2013 – In clinical trials with telaprevir (TLV) and boceprevir (BOC) renal impairment was not reported as a relevant adverse event. The PAN study is a noninterventional study enrolling patients treated with peginterferon alfa‐2a/ribavirin (PEG/RBV) with or without TVL or BOC. Here we restrict the analysis to hepatitis C virus genotype 1 patients having completed 12 (n = 895) or 24 weeks (n = 591) of treatment.

Peter Fickert, Elisabeth Krones, Marion J. Pollheimer, Andrea Thueringer, Tarek Moustafa, Dagmar Silbert, Emina Halilbasic, Min Yang, Hartmut Jaeschke, Geurt Stokman, Rebecca G. Wells, Kathrin Eller, Alexander R. Rosenkranz, Gosta Eggertsen, Carsten A. Wagner, Cord Langner, Helmut Denk, Michael Trauner – 28 June 2013 – Tubular epithelial injury represents an underestimated but important cause of renal dysfunction in patients with cholestasis and advanced liver disease, but the underlying mechanisms are unclear.

Helen S. Te – 28 June 2013

Shiv Kumar Sarin, Chandan Kumar – 28 June 2013

Alexander Wree, Akiko Eguchi, Matthew D. McGeough, Carla A. Pena, Casey D. Johnson, Ali Canbay, Hal M. Hoffman, Ariel E. Feldstein – 28 June 2013 – Inflammasome activation plays a central role in the development of drug‐induced and obesity‐associated liver disease. However, the sources and mechanisms of inflammasome‐mediated liver damage remain poorly understood. Our aim was to investigate the effect of NLRP3 inflammasome activation on the liver using novel mouse models.